129P Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score by Kushner, B., Mora, J., Chan, G., Morgenstern, D.A., Amoroso, L., Nysom, K., Faber, J., Wingerter, A., Bear, M., San Simón, A. Rubio, During, M., Tornøe, K.

Get full text

62MO Naxitamab pivotal clinical trial planned interim analysis of PFS and OS in patients with relapsed or refractory high-risk neuroblastoma by Mora, J., Chan, G.C., Morgenstern, D.A., Amoroso, L., Nysom, K., Faber, J., Wingerter, A., Bear, M., Rubio San Simon, A., Tornøe, K., Sørensen, P.S., Kushner, B.

Get full text

109P Impact of anti-drug antibody (ADA) on naxitamab efficacy and safety by Kushner, B., Chan, G.C., Morgenstern, D.A., Amoroso, L., Nysom, K., Faber, J., Wingerter, A., Bear, M., Rubio San Simon, A., Tornøe, K., Sørensen, P.S., Mora, J.

Get full text

Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes by Muir, E.M, Adcock, K.H, Morgenstern, D.A, Clayton, R, von Stillfried, N, Rhodes, K, Ellis, C, Fawcett, J.W, Rogers, J.H

Get full text

Large impacts, past and future, of ozone-depleting substances on Brewer-Dobson circulation trends: A multi-model assessment by Polvani, L.M., Wang, L., Abalos, M., Butchart, N., Chipperfield, M.P., Dameris, M., Deushi, M., Dhomse, S.S., Jöckel, P., Kinnison, D., Michou, M., Morgenstern, O., Oman, L.D., Plummer, D.A., Stone, K.A.

Get full text